Drugs primed for July PBS listing

Posted 20 June 2025 AM

At least seven medicines, ranging from first-in-class treatments to biosimilars of big earning brands are primed for a July PBS listing.

At the front of the que is Servier Laboratories’ IDH1 inhibitor Tibsovo for the treatment of locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation, in patients who have previously progressed on chemotherapy.

To see the whole article, please login

Popular

Five MDs to talk at new event

Who's relocated to the CBD?

Pharma moves into OTC market

Novartis drug to dominate sector

Latest Jobs

Medical Affairs Associate

Logistics Coordinator

Forklift Driver & Warehouse Assistant

Medical Science Liaison

Medical Advisor

See all...

Pharma in Focus Jobs

Marketing & Communications (2)

Sales & Customer Relations (9)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (3)

Other (12)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now